Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fulvia Ceccarelli

Showing results (191-200 of 199) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 199 results.
Rheumatology (Oxford, England)|November 8, 2013
The Italian MSUS Study Group recommendations for the format and content of the report and documentation in musculoskeletal ultrasonography in rheumatologyAnnamaria Iagnocco, Francesco Porta, Giovanna Cuomo, et al.
The Journal of Rheumatology|July 1, 2024
Anifrolumab in Refractory Systemic Lupus Erythematosus: A Real-World, Multicenter StudyChiara Tani, Chiara Cardelli, Margherita Zen, et al.
The Journal of Rheumatology|July 6, 2007
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA studyLuana Mancarella, Francesca Bobbio-Pallavicini, Fulvia Ceccarelli, et al.
Journal of Autoimmunity|September 23, 2017
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide studyLuca Iaccarino, Laura Andreoli, Elena Bartoloni Bocci, et al.
Frontiers in Cardiovascular Medicine|March 16, 2019
First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry)Micaela Fredi, Laura Andreoli, Beatrice Bacco, et al.
Journal of Autoimmunity|October 2, 2021
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohortMariele Gatto, Francesca Saccon, Laura Andreoli, et al.
The Lancet. Rheumatology|February 8, 2026
Patient profiles and early response in patients with systemic lupus erythematosus initiating anifrolumab: interim analysis from the ongoing multicentre observational REVEAL studyChiara Tani, Chiara Cardelli, Luca Moroni, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 11, 2020
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life SettingMariele Gatto, Francesca Saccon, Margherita Zen, et al.
Journal of Personalized Medicine|April 28, 2023
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS)Margherita Zen, Mariele Gatto, Roberto Depascale, et al.
Pageof 20

Showing results (191-200 of 199) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 199 results.
Rheumatology (Oxford, England)|November 8, 2013
The Italian MSUS Study Group recommendations for the format and content of the report and documentation in musculoskeletal ultrasonography in rheumatologyAnnamaria Iagnocco, Francesco Porta, Giovanna Cuomo, et al.
The Journal of Rheumatology|July 1, 2024
Anifrolumab in Refractory Systemic Lupus Erythematosus: A Real-World, Multicenter StudyChiara Tani, Chiara Cardelli, Margherita Zen, et al.
The Journal of Rheumatology|July 6, 2007
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA studyLuana Mancarella, Francesca Bobbio-Pallavicini, Fulvia Ceccarelli, et al.
Journal of Autoimmunity|September 23, 2017
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide studyLuca Iaccarino, Laura Andreoli, Elena Bartoloni Bocci, et al.
Frontiers in Cardiovascular Medicine|March 16, 2019
First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry)Micaela Fredi, Laura Andreoli, Beatrice Bacco, et al.
Journal of Autoimmunity|October 2, 2021
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohortMariele Gatto, Francesca Saccon, Laura Andreoli, et al.
The Lancet. Rheumatology|February 8, 2026
Patient profiles and early response in patients with systemic lupus erythematosus initiating anifrolumab: interim analysis from the ongoing multicentre observational REVEAL studyChiara Tani, Chiara Cardelli, Luca Moroni, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 11, 2020
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life SettingMariele Gatto, Francesca Saccon, Margherita Zen, et al.
Journal of Personalized Medicine|April 28, 2023
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS)Margherita Zen, Mariele Gatto, Roberto Depascale, et al.
Pageof 20